Clinical trials: MAFLD
Metabolic-associated Fatty Liver Disease
Efficacy and Safety of Rifaximin in Treating MAFLD
Study Objective: to evaluate the efficacy and safety of rifaximin in the treatment of metabolic-associated fatty liver disease (MAFLD), and investigate the underlying mechanisms by which rifaximin influence MAFLD progression.
- Trial name
- NCT07185932
- Testing
- Rifaximin (Xifaxan)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Changzheng Hospital
MASLD
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II clinical trial that consists of two parts.
- Trial name
- NCT07024212
- Testing
- DR10624 Injection
- Where
- 4 sites in China, Hong Kong
- Volunteers
- 110 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
MAFLD
Clinical Study on the Treatment of MAFLD With Ganzhixiao Capsules
This trial is expected to enroll 138 MAFLD patients in one clinical center, who will be randomly divided into a placebo group and a Ganzhixiao capsule group in a 1:1 ratio.
- Trial name
- NCT06848907
- Testing
- ganzhixiao capsule
- Volunteers
- 138 people
- Sponsor
- Dong Hui
Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH)
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches.
- Conditions
- Metabolic Associated Fatty Liver Disease, Metabolic Associated-dysfunction Steatohepatitis (MASH), Obesity
- Trial name
- METAfoie (NCT06764056)
- Testing
- semaglutide, Diet
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Non-Alcoholic Fatty Liver Disease
The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a liver condition primarily driven by metabolic dysfunctions that may progress to hepatitis, cirrhosis, and hepatocellular carcinoma.
- Trial name
- NCT06717828
- Testing
- Tai Chi Exercise, Regular Exercise, Control
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fujian Provincial Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic Syndrome
ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study
The ENDOCARE-SCREEN study is a single-center, observational, cross-sectional screening study designed to assess the prevalence, phenotypes, and determinants of metabolic dysfunction-associated steatotic liver disease…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic Syndrome, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- ENDOCARE-SCREE (NCT07336563)
- Where
- Poland
- Volunteers
- 10,000 people
- Sponsor
- Jarosław Drobnik
MAFLD, Metabolic Abnormalities
Frequency of MAFLD and Its Association With Nutritional Status and Metabolic Risk Factors in a Rural Population of Bangladesh
Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly recognized cause of chronic liver disease and is closely linked with obesity, metabolic abnormalities, and nutritional status.
- Conditions
- MAFLD, Metabolic Abnormalities, Obesity & Overweight
- Trial name
- NCT07470749
- Where
- Bangladesh
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
MAFLD, Fatty Liver
Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)
This RCT investigates the impact of Ganoderma lucidum on antioxidant staus, NRF2 levels and lipid metabolism in individuals with Metabolic Associated Fatty Liver Disease.
- Conditions
- MAFLD, Fatty Liver, Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver, Nonalcoholic
- Trial name
- GL-MAFLD-NFR2 (NCT07564947)
- Testing
- Ganoderma lucidum
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- University of Agriculture, Peshawar
Essential Phospholipid in Metabolic Associated Fatty Liver Disease
Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD
To evaluate the efficacy of Essential phospholipid versus Betaine HCL/L-Glutamic Acid in MAFLD
- Trial name
- EssenMAFLD (NCT07194863)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assiut University
MAFLD, AI (Artificial Intelligence)
AI Models vs Non-Invasive Fibrosis Scores in MAFLD Diagnosis
This study evaluates the accuracy of artificial intelligence (AI) models using FibroScan and clinical data to predict hepatic fibrosis in Egyptian patients with metabolic-associated fatty liver disease (MAFLD).
- Trial name
- MAFLD-AI (NCT07305636)
- Where
- Egypt
- Volunteers
- 522 people
- Sponsor
- Tanta University
Metabolic-associated Fatty Liver Disease (MAFLD)
Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study
The goal of this observational study is to learn the effectiveness and safety of the use of Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the pathogenetic therapy of metabolic-associated fatty liver disease…
- Trial name
- NCT06078722
- Where
- 7 sites in Kazakhstan
- Volunteers
- 264 people
- Sponsor
- Kazakh Association of Internal Medicine Specialists
Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-associated Fatty Liver Disease
- Trial name
- NCT07632677
- Testing
- iLivTouch (Vibration-controlled transient elastography)
- Where
- 22 sites in China
- Volunteers
- 10,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases
Management of risk factors is the primary approach to prevent cardiovascular disease (CVD). In this regard the accurate scoring of disease risk is fundamental.
- Trial name
- Endo-NAFLD (NCT06392828)
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- IMDEA Food
MAFLD
Liver Stiffness Changes by iLivTouch to Predict Liver-Related Events in MAFLD
This is an observational study (multicenter retrospective real-world cohort study). The purpose of this study is to assess the predictive performance of liver stiffness measurement (LSM, including baseline LSM1, current LSMC and…
- Trial name
- MAFLD (NCT07777198)
- Volunteers
- 2,303 people
- Sponsor
- Beijing Friendship Hospital
Type 2 Diabetes (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease
Cardiovascular Risk in T2DM With MAFLD: A Cohort Study
This study aims to address the following key scientific question by establishing a large-scale, high-standard clinical cohort: the independent contribution of MASLD and its progression to liver fibrosis on cardiovascular outcomes…
- Trial name
- NCT07706010
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
NAFLD
Impact of NAFLD vs MAFLD Stigma on Quality of Life in Egyptian Patients
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of liver disease worldwide. The global burden of NAFLD is about 30% of the population, With a higher prevalence in Egypt about 47.5 %.
- Trial name
- NCT06503068
- Testing
- Questionnaire
- Where
- Egypt
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tanta University
Hepatitis B, Chronic
Relationship Between MAFLD and Liver Fibrosis Progression in Patients With Chronic Hepatitis B: a Multicenter Retrospective Cohort Study
This multicenter retrospective study aims to study the association between the presence of MAFLD and change in liver stiffness over time in untreated and treated patients with chronic hepatitis B
- Trial name
- MAFLD-HBV 1 (NCT05708560)
- Where
- 3 sites in Netherlands
- Volunteers
- 800 people
- Sponsor
- Erasmus Medical Center
Metabolic Dysfunction-associated Fatty Liver Disease
Efficacy and Safety of Calculus Bovis Sativus in Adults With MAFLD
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become the most common chronic liver disease worldwide. Timely therapeutic intervention for MAFLD is crucial for improving patient prognosis and preventing its…
- Trial name
- NCT07085962
- Testing
- Calculus bovis sativus
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Huazhong University of Science and Technology
Metabolic Associated Fatty Liver Disease
Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study
The goal of this single arm, prospective study is to test the therapeutic response of oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks in non-diabetic MAFLD patients.
- Trial name
- NCT05782972
- Testing
- dapagliflozin (Forxiga)
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Liver Enzymes, Glucose Levels
Flaxseed Oil, Olive Oil, and Their Combination on Hepatic and Metabolic Outcomes in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease
This 16-week randomized controlled trial evaluated the effects of flaxseed oil, extra virgin olive oil, and their combination on biochemical hepatic and metabolic outcomes in patients with MAFLD.
- Conditions
- Liver Enzymes, Glucose Levels, Lipid Profile
- Trial name
- NCT07837323
- Testing
- Conventional diet+treatment, flaxseed oil, extra virgin olive oil
- Where
- Pakistan
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Lahore